Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China
No brand direct-acting antiviral agents (DAAs) are available for treatment of HIV-1/HCV co-infected patients in China. This study aimed to observe the therapeutic efficacy and safety of generic DAAs for affected Chinese patients.
Real-world setting to elucidate whether DAAs were tolerated and effective in HIV-1/HCV co-infected patients.
176 HIV-1/HCV co-infected patients received anti-HCV DAA treatment together with ART regimens for HIV infection. Among the 176 patients, 99 patients were treated with SOF + DCV ± RBV, 60 patients were treated with SOF + LDV ± RBV, and 17 patients received SOF + RBV ± Peg-IFN regimens, for 12 or 24 weeks, respectively. The primary endpoint was undetectable HCV RNA 12 weeks after therapy was completed (SVR12). Data pertaining to safety and adverse events were analyzed.
151/176 HIV-1/HCV co-infected patients finished the treatment and 12-week follow-up. SVR12 for the patients treated with regimens of SOF + DCV, SOF + DCV+RBV, SOF + Peg-IFN+RBV, SOF + RBV, SOF + LDV, and SOF + LDV+RBV for 12 or 24 weeks was 100% (75/75), 100% (11/11), 100% (14/14), 100% (2/2), 95.2% (40/42), and 100% (7/7), respectively. HIV-1/HCV co-infected patients with liver cirrhosis achieved well SRV12. Notably, there was no significant difference in adverse effects among patients with different baseline CD4+ T-cell count in those who received DAA regimens with or without Peg-IFN and RBV.
We showed generic SOF + DCV and SOF + LDV regimens were well tolerated and with high efficiency. Patient’s baseline CD4+ T-cell count did not exhibit significant difference in adverse effects.
KeywordsGeneric DAAs SOF Hepatitis C HIV-1 patients Co-infected
Yuanyuan Li, Linghua Li, and Jun Liu contributed equally as co-first authors. Fu-Sheng Wang contributed to the design of this study. All authors contributed to data collection, the interpretation of data, the drafting, and revision of this manuscript. The final version of this manuscript was approved by all authors.
This study was supported by The National Natural Science Foundation of China (No. 81601731).
Compliance with ethical standards
Conflict of interest
Yuanyuan Li, Linghua Li, Jun Liu, Da-Wei Zhang, Fang Zhao, Li Wang, Aizezi Mahemure, Ronghui Xie, Suyun Lei, Weiping Cai, Xicheng Wang, Zhanjun Shu, Xiejie Chen, Hui Wang, and Fu-Sheng Wang declared that there were no conflicts regarding funding or interest with this manuscript.
This study protocol had been approved by the ethical committee of the Beijing 302 hospital and other institutions involved.
- 4.Data Collection on Adverse Events of Anti HIVdSG, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A: D Study. AIDS 2010;24(10):1537–1548. https://doi.org/10.1097/qad.0b013e32833a0918 CrossRefGoogle Scholar
- 7.Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351(5):451–459. https://doi.org/10.1056/NEJMoa032653 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P. 12 weeks of daclatasvir in combination with sofosbuvir for HIV–HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis 2016;62(12):1489–1496. https://doi.org/10.1093/cid/ciw163 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313(12):1232–1239. https://doi.org/10.1001/jama.2015.1373 CrossRefPubMedGoogle Scholar
- 15.Zhang F, Zhu H, Wu Y, Dou Z, Zhang Y, Kleinman N, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–2012: a retrospective observational cohort study. Lancet Infect Dis 2014;14(11):1065–1072. https://doi.org/10.1016/S1473-3099(14)70946-6 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 2016;62(6):683–694. https://doi.org/10.1093/cid/civ948 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the ASTRAL-5 study. Liver Int 2017;37(12):1796–1804. https://doi.org/10.1111/liv.13462 CrossRefPubMedGoogle Scholar